Takeda's Kapidex: Can A Study On Plavix Shake Up The PPI Market?
This article was originally published in The Pink Sheet Daily
Executive Summary
Study of how several PPIs might affect the pharmacokinetics and pharmacodynamics of Plavix could impact formulary placement.
You may also be interested in...
BMS/Sanofi-Aventis To Study Plavix Efficacy Concerns
Genetics and concomitant PPI use are possible reasons for the anti-platelet drug’s reduced effectiveness in some patients, according to an FDA “Early Communication.”
Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review
Aetna is developing a clinical alert for physicians and pharmacists to warn about potentially reduced effectiveness for Plavix (clopidogrel) when the antiplatelet drug is used concurrently with a proton pump inhibitor, such as Prilosec (omeprazole) or Nexium (esomeprazole)
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.